Pharmaceutical Investing Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006
Pharmaceutical Investing Idera Pharmaceuticals Enters into a Clinical Development Support Agreement with Pillar Partners Foundation to Expand the Clinical Research on IMO-2125
Pharmaceutical Investing Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
Pharmaceutical Investing Cellectar Granted Seminal U.S. Patent for Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles
Pharmaceutical Investing Epizyme Reports Fourth Quarter and Full Year 2017 Operating Results and 2018 Milestones
Aduro Announces Milestone Achieved under Merck Collaboration for Initiation of Anti-CD27 Phase I Trial in Advanced Solid Tumors
Pharmaceutical Investing Loxo Oncology Announces Publication of Larotrectinib Clinical Data in The New England Journal of Medicine
Charbone Hydrogene signe une entente de conditions pour une facilite de credit de construction de 50 millions USD
